NovaBiotics

NovaBiotics is a clinical-stage biotechnology company developing first-in-class anti-infective therapies for difficult-to-treat infectious diseases, with a focus on antimicrobial resistance.

Its pipeline is built on two proprietary platforms: an anti-infective peptide platform yielding antifungal and antibacterial candidates, and a cysteamine-based aminothiol platform producing antibacterial, antiviral, and mucolytic compounds.

Lead assets include programmes targeting cystic fibrosis-associated respiratory infections, community-acquired pneumonia, and mycobacterial disease. The company also operates a consumer health division.